Increased blood-based intratumor heterogeneity (bITH) is associated with unfavorable outcomes of immune checkpoint inhibitors plus chemotherapy in non-small cell lung cancer

BACKGROUND: The combination of immune checkpoint inhibitors (ICIs) and chemotherapy has been the standard first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with driver-gene negative. However, efficacy biomarkers for ICIs-based combination therapy are lacking. We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Juan, Bao, Minwei, Gao, Guanghui, Cai, Yiran, Wu, Lihong, Lei, Lei, Zhao, Jing, Ji, Xianxiu, Huang, Ying, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335993/
https://www.ncbi.nlm.nih.gov/pubmed/35902848
http://dx.doi.org/10.1186/s12916-022-02444-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335993/
https://www.ncbi.nlm.nih.gov/pubmed/35902848
http://dx.doi.org/10.1186/s12916-022-02444-8

Ejemplares similares